Teclistamab densitization of donor-specific antibodies in aplastic anemia before haploHCT
Spoiler alert: it works, and yes, lower doses were used 😉
Our paper is out in Early View | @Haematologica
https://t.co/U8nBJR5yfp
We want our patients as fit as possible when we transplant them!
If aza+ven can get them there without beating them up, we'd take it 🙌🏽
@COSTEMCongress
Finally our academic POC CD19 #CARTcell investigator initiated phase 1-2 trial for adults with ALL has been approved!
Evidence that it IS possible to conduct IITs in Latin America.
Hoping to start enrolling 🔜
So proud of the Hematology team at UANL in Monterrey! Always at the forefront, always moving forward to improve the care and treatment of patients with hematologic diseases. Congratulations on your outstanding work! 🩸👏🏼
@GomezDLeonMD@dgomezalmaguer@PerlaRcp@yadithlopezz
We have a cure definition for myeloma.
Requires:
1) Off all therapy and sustained MRD negative for 5 years
2) Negative imaging studies
Presented by @NikhilMunshiMD#IMS26@Myeloma_Society
Note:
1) We need to see how this definition performs. Relapse rate for patients meeting these cure criteria must ideally be less than 5%. If not, we may have to adjust the criteria.
2) I hope the cure criteria will be the impetus to stop doing trials with endless therapy. You cannot claim cure with continuous therapy. I’m glad the field is mostly aligned on this.
Cure for patients and public in any disease has a deep meaning. Cure means cure. We cannot dilute it.
The world is unfair and inequitable. We know this impacts patient outcomes.
But what can we do about it?
Read our paper Strategies to overcome inequities in patients with hematologic malignancies for free here: https://t.co/MrE8HuuIs1 @cadelacruzd
Carlos Alcaraz va a ser uno de los mejores jugadores de la historia. Con 23 años ya ganó casi todo.
Sufrió una lesión difícil de transitar y se animó a volver en un Grand Slam, con todo lo que eso implica.
Perdió un partidazo, saludó con respeto y cercanía a su rival. Segundos después fue de la cancha con una sonrisa.
Un verdadero ejemplo como profesional y como humano.
Por más deportistas con el talento, la simpatía y el carisma del murciano.
To the students looking beyond their borders: there’s a place for you here!
@Forbes incluyó al @TecdeMonterrey entre las 15 mejores universidades internacionales para estudiantes de Estados Unidos, por nuestra experiencia global y modelo educativo. Somos la única universidad de América Latina en esta lista, junto a instituciones como @Cambridge_Uni, @UniofOxford, @mcgillu, @sciencespo, @yonsei_u y @waseda_univ, entre otras.
Recibimos a jóvenes de todo el mundo, con programas que pueden cursarse completamente en inglés y una experiencia global desde el primer día. Nos enorgullece que el mundo mire al Tec. Más aún, que encuentre aquí una comunidad de talento extraordinario que aprende, cuestiona, crea y abre camino todos los días.
Bienvenidas y bienvenidos. Les esperamos con los brazos abiertos.
https://t.co/vZDPReQ9qG
@ASanchez_PS@davserantes Thank you for the opportunity to present the case!! I had a lot of fun! And thanks to @davserantes for guiding us through it! 😎
Very grateful for this month!!! 🫀🫁🩸 So many cool IM cases and great teaching!! Lucky to learn from such an amazing hospitalist and mentor 👇🏼. Thank you!
Great ECG case with @monse_reyeslo today! ⚡️
A young human presented 6 months ago for palpitations, at which time baseline ECG available.
1 month PTA, presented for pleuritic CP, worse when flat/leaning forward → ECG #2 taken → given colchicine ⊕ ibuprofen ⊕ prednisone ...
2. Orthostasis 🔴 : can't-miss causes in pt who came in with multifocal strokes & recent Dx of pancreatic ductal adenocarcinoma?
3. Aspiration 🗣️ : how to differentiate chemical pneumonitis vs. true pneumonia, & how does one acquire these syndromes?
Medicine is awesome!
Today on med consults with @monse_reyeslo! 📟
1. Hypoxemia 🫁 : expiratory wheeze only on forced exhalation in a pt with vocal cord dz & remote trach after MVA trauma. One for the @Dx_Atypia show ...
In the US we argue CAR-T vs bispecifics while 36% of Latin America fights for access to rituximab.
Let that sink in.
GELL Survey 2025 — 73 centers, 16 countries:
73% highly restricted access to bispecifics
~0% commercial CAR-T outside Brazil
Only 15% have NGS
Only 35% access to clinical trials
We’re having 2026 debates with early 2000s access.
The real question isn’t CAR-T vs bispecifics. It’s: how do we close this gap?
Sobering data presented by @DrMCanales here in Chile. @LymphomaEx
Colunga-Pedraza et al. Blood 2025;146(Suppl 1):6193
#Lymphoma #DLBCL #LATAM #GlobalOncology #HealthEquity